Microfluidic Liposome Synthesis with On-Chip Microdialysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional bulk synthesis techniques for liposomes are cumbersome, time-consuming, and result in large, polydisperse nanoparticles with limited shelf life due to drug leakage and lipid degradation, making it difficult to achieve controlled vesicle size and high drug loading efficiency for effective drug delivery.
Innovation Solution
A microfluidic system utilizing high aspect ratio hydrodynamic flow-focusing (HAR-MHF) and on-chip microdialysis for continuous flow synthesis and active loading of liposomes, enabling rapid formation and loading of nanoscale vesicles with high drug-to-lipid ratios and low polydispersity, and providing a platform for high-throughput production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional bulk synthesis techniques are used for liposome preparation, then the process is simple to implement, but the resulting liposomes are large, polydisperse, and have limited shelf life due to drug leakage and lipid degradation
Solution Approach 1:
The patent replaces conventional mechanical bulk synthesis methods with a microfluidic system that uses controlled fluid flow and hydrodynamic focusing to form liposomes. This substitution enables precise control over vesicle size and polydispersity while maintaining processability through automated continuous flow operation.
Solution Approach 2:
The synthesis process is segmented into distinct functional regions within the microfluidic device: a liposome formation region where vesicles are generated, a purification region where free drug is removed, and a loading region where active drug is encapsulated. This segmentation allows each step to be optimized independently while achieving overall process precision.
2Productivity
If conventional bulk synthesis techniques are used, then fewer processing steps are required, but drug loading efficiency is low and shelf life is limited
Solution Approach 1:
The microfluidic system operates in continuous flow mode, allowing liposome formation, purification, and drug loading to occur simultaneously in different regions of the device. This eliminates the sequential batch processing steps of conventional methods, dramatically improving productivity while reducing total process time through parallel operation.
Solution Approach 2:
Liposomes are formed and purified of free drug before active drug loading occurs. This preliminary preparation ensures that the liposomes are ready for efficient drug encapsulation, maximizing drug loading efficiency while minimizing the time required for each subsequent step.
3Manufacturing precision
If conventional bulk synthesis is used, then the process is fast to initiate, but the liposomes produced are polydisperse and have poor therapeutic indices
Solution Approach 1:
The patent controls liposome size and polydispersity by adjusting key parameters of the microfluidic system including flow rates of lipid and buffer solutions, channel geometry, and mixing conditions. These parameter changes enable precise control over vesicle formation while maintaining ease of manufacture through systematic optimization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microfluidic system enables the production of monodisperse liposomes with controlled sizes and high drug loading efficiency, improving therapeutic indices and safety profiles by allowing for precise control over vesicle size and drug concentration, suitable for large-scale in vivo studies and clinical applications.
Implementation Method 1
a microfluidic system utilizes high aspect ratio hydrodynamic flow-focusing (HAR-MHF) and on-chip microdialysis for continuous flow synthesis and active loading of liposomes
Implementation Method 2
The microdialysis region may comprise a counterflow channel adjacent to the sample flow channel, and a membrane in between or intermediate the sample flow channel and the counterflow channel. The membrane permits buffer exchange between the sample flow channel and the counterflow channel and establishes a transmembrane ion gradient.
Implementation Method 3
The first agent is mixed with the liposomes received from the transmembrane gradient formation region, and actively loaded within intravesicular spaces of the liposomes.
Data Source
AI summary
Microfluidic methods and systems are provided for continuous flow synthesis and active loading of liposomes, which include a liposome formation region configured to form a population of liposomes and a microdialysis region downstream from the liposome formation region and configured to form a transmembrane gradient for active drug loading of the liposomes. Microfluidic methods and systems for high throughput production of liposomes are also provided featuring high aspect ratio microchannels.